All In Biotech

Drug Trial Radar · NCT05736107

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

A Randomized, Placebo-Controlled, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Last checked: Nov 19, 2026Latest source record: Jul 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

May 30, 2023

Primary completion

May 20, 2024

Study completion May 20, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing subcutaneous fat.

Conditions

  • Subcutaneous Fat

Interventions

  • CBL-514 InjectionDrug

    Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.

  • 0.9% Sodium ChlorideOther

    Sodium Chloride (0.9% NaCl) placebo for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants with at least 1-grade improvement reported by Investigator using the Clinician-Reported Abdominal Fat Rating ScaleTime frame: From baseline to 12 weeks after the final treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational site 1

    Pflugerville, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.